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Introduction: There is a 10-year gap in life expectancy
between Aboriginal and non-Aboriginal Australians. The
leading cause of death for Aboriginal Australians is
cardiovascular disease, including myocardial infarction
and stroke. Although atrial fibrillation (AF) is a known
precursor to stroke there are no published studies about
the prevalence of AF for Aboriginal people and limited
evidence about AF in indigenous populations globally.
Methods and analysis: This mixed methods study
will recruit and train Aboriginal health workers to use
an iECG device attached to a smartphone to
consecutively screen 1500 Aboriginal people aged
45 years and older. The study will quantify the
proportion of people who presented for follow-up
assessment and/or treatment following a non-normal
screening and then estimate the prevalence and age
distribution of AF of the Australian Aboriginal
population. The study includes semistructured
interviews with the Aboriginal health workers about the
effectiveness of the iECG device in their practice as well
as their perceptions of the acceptability of the device
for their patients. Thematic analysis will be undertaken
on the qualitative data collected in the study. If the
device and approach are acceptable to the Aboriginal
people and widely adopted, it may help prevent the
effects of untreated AF including ischaemic stroke and
early deaths or impairment in Aboriginal people.
Ethics and dissemination: This mixed methods
study received ethics approval from the Aboriginal
Health and Medical Research Council (1135/15) and
the Australian Health Council of Western Australia
(HREC706). Ethics approval is being sought in the
Northern Territory. The findings of this study will be
shared with Aboriginal communities, in peer reviewed
publications and at conferences. There are Aboriginal
investigators in each state/territory where the study is
being conducted who have been actively involved in
the study. They will also be involved in data analysis,
dissemination and research translation.
Trial registration number: ACTRN12616000459426.
INTRODUCTION
Aboriginal and/or Torres Strait Islanders
(hereafter Aboriginal) are the indigenous
people of Australia and die on average
10 years earlier than other Australians. With
signiﬁcantly higher rates of infant mortality,
suicide and chronic disease, improving
health outcomes in this population is a key
priority for healthcare providers and govern-
ments.1 Many Aboriginal Australians access
the healthcare system in the late stages of the
disease process or in emergencies due to
fear, racism and service access.2 3 The
Australian Government has a national strat-
egy, Closing the Gap, which has established
goals to close the gap in life expectancy for
Aboriginal Australians within a generation.
The strategy includes social determinants as
well as speciﬁc health-related targets. The
Prime Minister of Australia reports annually
on progress toward meeting the Closing the
Gap targets.1
Strengths and limitations of this study
▪ There is a 10-year life expectancy gap between
Aboriginal and non-Aboriginal Australians and
cardiovascular disease is a leading cause of early
death and impairment.
▪ The study intends to estimate the prevalence and
age distribution of known and unknown atrial fib-
rillation (AF) in Aboriginal people in Australia and
determine the acceptability of the portable iECG
device.
▪ This study uses technology which is proven to
be effective in the detection of AF, was designed
in collaboration with Aboriginal health organisa-
tions and is informed by the best available evi-
dence about effective detection and treatment of
health issues in Australian Aboriginal people.
▪ The study is novel as there are no studies about
the prevalence of AF in Aboriginal people and the
study design uses Aboriginal health workers to
conduct consecutive opportunistic screenings
using the iECG in the course of their usual duties.
▪ The study will contribute to the global evidence
on indigenous peoples and AF.
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Free healthcare is available in Australia.4 In addition,
Aboriginal Community Controlled Health Services were
established from 1971 to provide culturally speciﬁc
primary healthcare services5 and all public healthcare
services have explicit obligations with respect to meeting
the needs to Aboriginal patients.3 6 Aboriginal employ-
ees in the healthcare system, including Aboriginal
Health Workers, play a key role in the provision of cul-
turally competent healthcare for Aboriginal people.
Aboriginal Health Workers provide primary healthcare
and health literacy, and often act as brokers for
Aboriginal people accessing healthcare services.7
Despite signiﬁcant efforts to improve Aboriginal
health outcomes, Aboriginal Australians have very high
rates of cardiovascular disease particularly myocardial
infarction and stroke.8 9 Cardiovascular disease remains
the leading cause of death for this population.10–12 The
burden of stroke for Aboriginal people is considerable
with Aboriginal people more likely than other
Australians to suffer a stroke.12 13 Atrial fibrillation (AF)
is the most common sustained arrhythmia, with adults
reaching the age of 40 years having a one in four life-
time chance of developing the arrhythmia.14 The risk of
AF increases with age and individuals affected by AF
have a ﬁve times higher risk of ischaemic stroke. Quality
of life is also signiﬁcantly worse for those with AF. One
of the principal health issues is that AF is associated with
∼1/3 of ischaemic strokes in Australia and Sweden.15 16
Strokes from AF are in general more severe than those
associated with other causes, with greater mortality and
disability if non-fatal. However, strokes associated with
AF are preventable, with a 64% reduction if oral anti-
coagulant is prescribed.17 18
AF prevalence in the Australian population is estimated
to rise signiﬁcantly over the next two decades.19 In
people with AF, both stroke and death are greatly
reduced by treatment with oral anticoagulant (by ∼64%
and 26% respectively).17 18 While AF can be associated
with symptoms, it is frequently asymptomatic which may
indicate that existing documented rates of AF in Australia
are a signiﬁcant underestimation of the scope of the
problem.20 21 To prevent strokes resulting from unknown
AF, screening for asymptomatic AF could be helpful.22
There is very limited information on the rates of AF in
Australian Aboriginal people, and the only studies
available have come from hospitalisation data after an
admission. These studies found a much higher
age-standardised incidence of AF in Aboriginal than in
non-Aboriginal patients. This is particularly marked in
the younger age groups, with ratios of age standardised
incidence rates of AF for Aboriginal people being 3.6 for
men and 5.4 for women compared to non-Aboriginal
people between the ages of 20 and 54 years. On average,
Aboriginal people develop AF almost 20 years earlier
than their non-Aboriginal counterparts, and even more
concerning is the high rate of associated comorbidities
found in this subset versus the wider Australian popula-
tion.20 21 Risk factors for AF such as hypertension,
diabetes, obesity, physical inactivity, chronic kidney
disease, acute rheumatic fever and rheumatic heart
disease are all more common in Aboriginal people and at
a younger age than in non-Aboriginal people.20 21 23 This
uneven burden of comorbidity results in CHA2DS2VASc
scores (a score developed to indicate risk of stroke) of
≥2, indicating risk sufﬁcient to recommend anticoagula-
tion in 53% of Aboriginal people aged below 55 years,
and 73% in those aged 55–64 years, compared to only
14% and 28%, respectively, in non-Aboriginal people of
the same age.20 Aboriginal people therefore face a
double jeopardy of increased AF incidence at a younger
age and an increased risk of stroke when AF occurs.20 21
Accordingly, our study will take a preventative
approach and opportunistically screen patients for AF at
a younger age, starting at 45 years, before associated car-
diovascular complications, like stroke, occur. Aboriginal
people 45 years and above make up just 18% of the
Aboriginal population in Australia.24 By comparison the
total Australian population aged 45 years and over is
39.6%.24 Previous studies have assessed symptomatic AF
in hospitalised patients, so our study is novel in that no
previous study has assessed the incidence of asymptom-
atic AF in Aboriginal people.20 21 25
There is some evidence in the literature for the efﬁ-
cacy of opportunistic screening in the sexual and repro-
ductive health of Aboriginal people.26–29 To be effective,
opportunistic screening must be undertaken in a cultur-
ally competent manner as the cultural competence of
the health service is associated with the likelihood that
Aboriginal people access services.30 Critically important
is that opportunistic screening must include pathways
for further assessment and treatment, and access must
be actively facilitated where necessary.31 Further, oppor-
tunistic screening should include improving health liter-
acy so that Aboriginal people are better informed about
their health and therefore more likely to identify poten-
tial health issues earlier.32 33 There are no studies of
opportunistic screening of Aboriginal people for cardio-
vascular disease or AF.
Our study will estimate the prevalence and age distri-
bution of asymptomatic AF in Aboriginal Australians.
There are a number of unique challenges in identifying
Aboriginal people with asymptomatic AF: the population
is small ( just under 3% of the Australian population)1
and is not reliably identiﬁed within the healthcare
setting; the population is also widely dispersed;34 less
likely to access healthcare services; likely to have lower
health literacy; and less likely to seek healthcare assess-
ment or treatment at the early signs.35 This study expli-
citly addresses each of these issues through use of a
portable single-lead iECG device (Kardia) which can be
used by a lay person with minimal training. The iECG
device has been successfully used by non-physician
health personnel in non-Aboriginal populations in
Australia.22 36–38
The overall goal of the study is to help prevent the
effects of untreated AF in Aboriginal people, particularly
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ischaemic stroke which may result in early death or
impairment. The study has three aims, to:
1. Determine the acceptability of the portable iECG
device to diagnose AF in Aboriginal people and facili-
tate access to further assessment and treatment;
2. Estimate the prevalence and age distribution of both
known and unknown AF in Aboriginal people in
Australia;
3. Improve health literacy in Aboriginal people and
iECG screeners.
As there is limited evidence about the prevalence of
AF in indigenous populations globally25 this study
should also contribute to the global picture of AF preva-
lence in indigenous peoples.
METHODS AND ANALYSIS
Study design
This is a mixed methods study. We will use quantitative
methods to determine the proportion of participants
with a non-normal result who presented for follow-up
assessment and treatment, and to estimate the preva-
lence and age distribution of AF in Aboriginal people.
Qualitative methods will be used to determine the
acceptability of the iECG as a screening tool for iECG
screeners and Aboriginal participants, and the effect of
the intervention on improving health literacy in
Aboriginal patients.
The study will take place in communities in New
South Wales, Northern Territory and Western Australia
in collaboration with Aboriginal Community Controlled
Health Services and other services which meet the
needs of Aboriginal people in those communities (eg,
hospital, dental service, pharmacy and community
centre). Each participating service will nominate local
Aboriginal health or health-related workers with a good
understanding of the local healthcare system and a will-
ingness to participate in the study.
Data collection method
The local Aboriginal healthcare workforce have been
identiﬁed to participate in the study as data collectors
because they are likely to be trusted by Aboriginal
people and have a high level of cultural competence,
understand the local health system and are likely to be
able to facilitate and expedite access to the local health
system. Cultural competence is well established in the lit-
erature as a critical factor in Aboriginal people partici-
pating in healthcare services.39–41 These workers will be
termed iECG screeners in this study. The iECG screen-
ers will receive training in the use of the iECG device,
consent processes, cardiovascular health promotion and
treatment, data collection and the clinical pathway for
patients with a non-normal result and will conduct the
screenings as part of their usual interactions with
patients in the community, home or clinic. There is
some evidence in the peer-reviewed literature for the
efﬁcacy of each of the study design elements with
Aboriginal people.27 29–31 42
The iECG has been chosen as the screening tool for
this study because it has been successful with other
populations,22 36–38 it is small (clips onto the back of
most smartphones); can be used by anyone with
minimal training; and records a single-lead ECG in
∼30 s. A validated algorithm allows reliable detection of
AF and other arrhythmias in real-time.22 This device
enables cost-effective community-based screening,
including rural and remote locations. The device is
accurate and Food and Drug Administration and
Therapeutic Goods Administration approved (ARTG
Identiﬁer 208100) and has been used in studies to iden-
tify AF in Metropolitan Sydney22 and Melbourne. After
the ECG is completed, the data is transmitted to the
password encrypted and HIPPAA compliant Kardia pro-
prietary server. Another account will store de-identiﬁed
ECG screening data for this study.
Participating health services will be supplied with the
iECG device and smartphone for each health worker
who will be undertaking screenings in the study. The
smartphone will have an activated sim card to enable
the iECG software to transmit the ECG via the telephone
data network. The participating health service will keep
the iECG device after the completion of the study to
beneﬁt their health service.
Sampling strategy
Gaining informed consent and conducting the screen-
ings will occur opportunistically within the course of
usual duties for a range of qualiﬁed and unqualiﬁed
iECG screeners. iECG screeners will invite consecutive
patients to participate in the study which should reduce
bias in the sample. A total of 1500 people represent 1%
of the Aboriginal population in Australia aged 45 years
and older and is therefore a reasonable sample to esti-
mate prevalence. If we assume a prevalence of AF of 3%
in this population, then the 95% CI of this would be
2.0% to 4.0% with this sample size.
Thirty iECG screeners will conduct 50 screenings on
eligible patients in order to reach a total of 1500 screen-
ings. Given the additional time required to gain
informed consent for patients to join the study and the
wide-ranging roles and responsibilities of Aboriginal
workers in the healthcare system, the study explicitly
limits each screener to 50 screenings. Once they have
completed the 50 screenings for the study they can
retain the device and use it in their usual practice.
The eligibility criteria for this study are:
1. Aboriginal heritage;
2. Aged 45 years or more;
3. Living in New South Wales, Northern Territory or
Western Australia.
Procedure
Eligible participants will be formally consented into the
study by an Aboriginal iECG screener. Participants will
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receive an information sheet explaining the study and a
plain English and pictorial information sheet setting out
the risk factors for cardiovascular disease, the ways to
reduce risk and promote heath, a straightforward
explanation of the symptoms of a heart disease and what
to do if experiencing those symptoms.
The iECG has three possible results normal, possible
AF or unclassiﬁed. Participants who record a result
other than normal will be referred for a conﬁrmatory
12-lead ECG and individual management plan. This
management plan will be supported by the iECG
screener and will proceed according to the agreed
pathway. The assessment and treatment pathways for
patients with a non-normal result will be negotiated,
agreed and documented with each community before
starting the study in that site. A registered nurse asso-
ciated with the study will review all cases where a patient
has a non-normal result, within 24 hours of the screen-
ing and take all steps to ensure that the participant has
accessed further assessment and treatment where indi-
cated. The registered nurse will follow-up with every
patient with a non-normal result and facilitate access to
further assessment and treatment where this is indicated.
The registered nurse will also record in a database
whether or not the patient with a non-normal iECG
attended for a 12-lead ECG, whether or not they had AF
and whether or not they knew they had AF prior to the
screening. The ﬁdelity of the intervention will be
assessed quantitatively by recording the number of
patients who do not complete the protocol and
qualitatively through interviews with iECG screeners and
the registered nurses.
Once the 1500 screenings have been completed, data
will be exported from the AliveCor server and analysed
to estimate the prevalence and age distribution of AF in
Aboriginal people in Australia. The interviewer-assisted
surveys will be conducted face-to-face or via telephone
with the iECG screeners by a member of the research
team. This will include, wherever possible, iECG screen-
ers who did not complete 50 screenings. The surveys will
identify the enabling factors and barriers for: (1)
Aboriginal workers using the iECG in the course of their
practice and (2) Aboriginal patients’ receptiveness to
the iECG as perceived by the iECG screeners.
Data analysis
Descriptive statistics (means and proportions including
their CIs) will be analysed using SPSS software, V.22
(SPSS , Chicago, Illinois, USA). The χ2 test will be used
to examine demographic differences including age and
sex.
The qualitative analysis will be based on published
methods for qualitative research in healthcare.43 All
interviews will be transcribed in full and downloaded
into NvivoV.11 for analysis.
ETHICS AND DISSEMINATION
Ethics approval is being sought in the Northern
Territory.
Figure 1 Flow chart of the study. NSW, New South Wales; NT, northern territory; RN, registered nurse; WA, Western Australia.
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It is a requirement of the Ethics Committee of the
Aboriginal Health and Medical Research Council that
Aboriginal communities are engaged prior to the study
to inform the study design. The process of working with
communities to design the study such that they could
write letters of support, took ∼9 months. The process
for this study is detailed in ﬁgure 1.
The ﬁndings of this study will be shared with
Aboriginal communities, the Aboriginal Health and
Medical Research Council, and in peer-reviewed publica-
tions and at conferences. The ﬁndings will also contrib-
ute to the global picture of AF prevalence and age
distribution, and if widely adopted will improve timely
detection and treatment of AF in Aboriginal people.
STRENGTHS AND LIMITATIONS OF THE STUDY
The strengths of the study are that it uses technology
which is proven to be effective in the detection of AF;
the study design was developed in collaboration
Aboriginal health organisations and is informed by the
best available evidence about effective detection of
health issues and treatment of Australian Aboriginal
people. However, the evidence for effective detection
and treatment of Aboriginal people is sparse and there
are no studies about opportunistic screening of
Aboriginal people for cardiovascular disease. The avail-
able evidence indicates that Australian Aboriginal and
New Zealand Maori populations experience AF at a
younger age than other populations. This study includes
Aboriginal people aged 45 years and older. Depending
on the ﬁndings of this study, future studies may include
younger people.
We are conducting opportunistic screening for known
and unknown AF in people accessing healthcare services
and are recruiting predominantly from rural and
remote parts of Australia, with some regional sites. This
will inevitably bias our sample. To reduce this we have
instructed our screeners to be as systematic as possible.
This will reduce the bias of haphazard or selective sam-
pling. While consecutive sampling is not equivalent to
random sampling it is appropriate for this population
group. Our sample will not be completely representative
of Aboriginal people across Australia as we are concen-
trating on rural and regional areas. The opportunistic
sampling and its potential compromise to representative-
ness is a limitation of the study.
Given the burden of cardiovascular disease borne by
Aboriginal Australians and the estimated signiﬁcant rise
of AF prevalence in Australia, this study is an important
next step in preventing premature death or impairment
of Aboriginal people from stroke. This mixed methods
study brings together the best available evidence on AF,
opportunistic screening and Aboriginal Australians to
estimate the prevalence and age distribution of known
and unknown AF in Aboriginal people in Australia and
determine the acceptability of the portable iECG
device.
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